abstract |
The present disclosure relates to HIF-1.alpha. prolyl hydroxylase inhibitors of Formula I (see formula I) wherein R, R1, R2, R3, R a and I, are as defined in the description, compositions which comprise the HIF-1.alpha. prolyl hydroxylase inhibitors of Formula I and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia using the compounds of Formula I. |